Drugmaker Says RSV Vaccine Well Tolerated, Effective In Higher Risk Adults Under 60

Reuters (4/9, Erman) reports, “Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated” in a late-stage trial “and generated an immune response in higher risk adults under the age of 60 similar to that in older adults.” CNN (4/9, Bonifield, Musa) reports that, in the trial, “a single dose of Abrysvo demonstrated an immune response that wasn’t inferior to the response in the trial of the RSV vaccine for older adults. Additionally, one month after vaccination, trial participants had increased levels of neutralizing antibodies against the two main RSV subtypes compared with levels before vaccination, the company said Tuesday.”